Develops and distributes drugs for rare diseases across Europe.
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Series A Amsterdam-based Avanzanite closed a €32M Series A from MVM Partners to scale rare disease treatments in Europe. | $37.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.